Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Childhood acute lymphoblastic leukemia.

Ching-Hon Pui1, Mary V Relling, Dario Campana

  • 1Department of Hematology-Oncology, St. Jude Children's Research Hospital, and Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. ching-hon.Pui@stjude.org

Reviews in Clinical and Experimental Hematology
|August 28, 2002
PubMed
Summary

Identifying drug-resistant childhood leukemia is key as cure rates rise. Measuring minimal residual disease (MRD) helps tailor treatments and improve outcomes for acute lymphoblastic leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome.

Blood advances·2022
Same author

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.

Blood·2022
Same author

Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.

Nature genetics·2022
Same author

Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.

JAMA oncology·2022
Same author

Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care.

Children (Basel, Switzerland)·2021

Area of Science:

  • Pediatric Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Childhood acute lymphoblastic leukemia (ALL) cure rates are improving, nearing 80%.
  • Focus is shifting towards identifying and overcoming drug resistance in ALL.
  • Understanding resistance mechanisms is crucial for developing targeted therapies.

Purpose of the Study:

  • To highlight the importance of identifying drug-resistant ALL cases.
  • To emphasize the role of pharmacodynamic and pharmacogenomic studies in personalizing ALL therapy.
  • To discuss the prognostic significance of minimal residual disease (MRD) assessment.

Main Methods:

  • Review of pharmacodynamic and pharmacogenomic studies.
  • Analysis of minimal residual disease (MRD) as a prognostic indicator.

Related Experiment Videos

  • Discussion of advances in biotechnology and bioinformatics for molecular diagnostics.

    • Main Results:

    • Minimal residual disease (MRD) measurement is the strongest independent prognostic factor in ALL.
    • MRD is influenced by leukemic cell drug sensitivity and host genetic factors.
    • Individualized therapy based on pharmacogenomics can enhance efficacy and reduce toxicity.

    Conclusions:

    • Accurate identification of drug resistance and understanding its mechanisms are vital for improving ALL outcomes.
    • Minimal residual disease (MRD) monitoring is essential for prognostication and treatment individualization.
    • Continued research and clinical trials are advancing the cure rates for childhood ALL.